Aviance Capital Management’s Cytosorbents Corp CTSO Stock Holding History

Aviance Capital Management’s Portfolio CTSO Stock Details CTSO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$1K	Sell	78 -13,626	-99%	-$106K	﹤0.01%	222
2018 Q4	$111K	Buy	+13,704	New	+$136K	0.02%	168
2017 Q4	–	Sell	-1,580	Closed	-$10K	–	281
2017 Q3	$10K	Hold	1,580	–	–	﹤0.01%	245
2017 Q2	$7K	Buy	+1,580	New	+$6.93K	﹤0.01%	267
2015 Q2	–	Sell	-43,034	Closed	-$568K	–	72
2015 Q1	$568K	Buy	+43,034	New	+$443K	0.02%	186

Other funds holding CTSO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Skylands Capital Milwaukee, Wisconsin $814M AUM 32.37% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

USAA

United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

Aviance Capital Management's CTSO Position: Q1 2019 in Review

Aviance Capital Management reduced its Cytosorbents Corp (CTSO) stake by 99% in Q1 2019, selling an estimated $106K and leaving 78 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #222.

Aviance Capital Management first reported a position in CTSO in Q1 2015 and has held it in 5 quarters since. The position peaked at $568K in Q1 2015. 77 funds tracked by Wall St. Rank hold CTSO as of Q1 2019.

Aviance Capital Management held 78 shares of Cytosorbents Corp worth $1K as of Q1 2019.
Aviance Capital Management sold 13,626 Cytosorbents Corp shares in Q1 2019, an estimated $106K.
Cytosorbents Corp made up ﹤0.01% of Aviance Capital Management's portfolio in Q1 2019, its #222 holding.
Aviance Capital Management first reported a position in Cytosorbents Corp in Q1 2015 and has held it in 5 quarters since.
Aviance Capital Management's Cytosorbents Corp position peaked at $568K in Q1 2015.
77 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q1 2019.

Based on Aviance Capital Management's 13F filing for Q1 2019, filed 15 May 2019.